Overview
Lobbying Costs
300,000€ - 399,999€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
0.6 Fte (3)
Lobbyists with EP accreditation
1
High-level Commission meetings
4
Lobbying Costs over the years
-
Info
Moderna, Inc.
EU Transparency Register
011080341579-06 First registered on 24 Feb 2021
Goals / Remit
Moderna’s mRNA technology quickly enabled us to pivot when the COVID-19 crisis emerged and to manufacture and deliver a safe, effective vaccine against COVID-19. In this context, Moderna concluded advance purchase agreements (APA) and contracts with the European Commission. Building on its mRNA platform, Moderna is also developing mRNA vaccines and therapies against other infectious diseases, and non-infectious diseases in oncology, rare diseases and other areas.
Main EU files targeted
EU Vaccines Strategy
European Health Emergency preparedness and Response Authority (HERA) & biopreparedness
Covid 19 vaccines policies & procurement mechanisms
Pharmaceutical Strategy for Europe
Revision of the EU general pharmaceuticals legislation
COVI Report on COVID-19 pandemic
Health technology assessment - joint clinical assessments of medicinal productsAddress
Head Office
200 Technology Square
Cambridge 02139
UNITED STATESEU Office
200 Technology Square
Cambridge 02139
UNITED STATESWebsite
-
People
Total lobbyists declared
3
Employment time Lobbyists 25% 2 10% 1 Lobbyists (Full time equivalent)
0.6
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
1 accreditations were / are live (in bold) for the selected state of 22 Nov 2024
Name Start date End Date Maren von Fritschen 16 Oct 2024 15 Oct 2025 Alexander DR. MEIER 18 Jan 2024 04 Oct 2024 Maren DR. VON FRITSCHEN 18 Jan 2024 04 Oct 2024 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
VE - Vaccines Europe (https://www.vaccineseurope.eu)
Eucope - European Confederation of Pharmaceutical Entrepreneurs AISBL (www.eucope.org)
IFPMA - International Federation of PHarmaceutical Manufacturers & Associations (www.ifpma.org)
BIO - Biotechnology Innovation Organization (www.bio.org)Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
300,000€ - 399,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount fipra international srl 100,000€ - 199,999€ fti consulting belgium 10,000€ - 24,999€ Intermediaries for current year
Name fti consulting belgium fipra international srl Closed year Costs
300,000€ - 399,999€
Other financial info
The estimate of annual costs related to activities covered by the register includes personal costs, the relevant percentage of trade associations membership fees and relevant costs for intermediaries, as declared above.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
Outreach emails to communicate Moderna announcements
Sponsored article in Politico on the mRNA technology and Moderna global health strategy
Science Business Roundtable (participation of officials from European Commission and members of EMA) – 27 April
Article for European Files Magazine (July edition)Other activities
None declared
Meetings
Meetings
4 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 03 Nov 2022 Location Bruxelles Subject Videoconference with Moderna CEO on future of mRNA platform; ongoing cooperation on the management of the pandemic Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Daphne von Buxhoeveden (Cabinet member)
- Stella Kyriakides (Commissioner)
-
Date 26 Nov 2021 Location Videoconference Subject Meeting with CEO of Moderna Cabinet Cabinet of President Ursula von der Leyen Portfolio President Attending - Ursula von der Leyen (President)
-
Date 10 Apr 2021 Location Videocall Subject Vaccine production and deliveries Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Thierry Breton (Commissioner)
Other Lobbyists -
Date 31 Jan 2021 Location Videoconference Subject Meeting with CEOs of the pharmaceutical companies with which the Commission has signed Advance Purchase Agreements Cabinet Cabinet of President Ursula von der Leyen Portfolio President Attending - Ursula von der Leyen (President)
Other Lobbyists